Although GlaxoSmithKline had the potential to further boost its position in NRT, the FTC required that Novartis divest its Habitrol
brand of NRT patches before the consumer health joint venture could be completed.
Reddy's Laboratories acquires Habitrol
Brand from Novartis
5% interest in the joint venture, and without the divestitures required by the proposed order it would continue to own the Habitrol
business, which had U.
At presently, GSK has its own nicotine replacement patch, Nicoderm CQ, a direct competitor of Habitrol
27 November 2014 - Swiss healthcare group Novartis AG (VTX:NOVN) has agreed to offload its nicotine patch unit, Habitrol
, to obtain clearance by the Federal Trade Commission (FTC) for its joint venture with UK peer GlaxoSmithKline plc (LON:GSK), the regulator said.
The contest is funded by the Government of Ontario with prize support provided by the makers of Thrive and Habitrol
2) Transdermal patch formulation previously marketed as Habitrol
There's the V-Chip, the Habitrol
nicotine patch, an electronic hearing implant, and Google.
The plaintiff's federal appellate brief in a Habitrol
case where the Oklahoma trial court held that that an exception to the learned intermediary rule exists where the FDA requires direct consumer warnings on prescription products.
The Institute for Safe Medication Practices (ISMP) issued the warning in the wake of an incident involving a patient who entered a MR scanner wearing a Habitrol
TABLE Transdermal Patch Comparison Dosage Trade Names Dosing Forms Available Habitrol
21 mg/day for 4 weeks, then 7,14, and 21 14 mg/day for 2 weeks, then mg/day patches 7 mg/day for 2 weeks Nicoderm, 21 mg/day for 6 weeks, then 7, 14, and 21 Nicoderm CQ 14 mg/day for 2 weeks, then mg/day patches Clear Nicoderm 7 mg/day for 2 weeks CQ Nicotrol 15 mg/16 hrs for 6 weeks 15 mg/16 hrs patch
Following the plaintiff's reasoning, the Oklahoma Supreme Court held that the FDA mandate of a direct patient warning created an exception to the learned intermediary doctrine, and imposed a common law duty on the Habitrol
manufacturer to provide an adequate warning to the patient directly.